Loading...

Brilliant Violet 510™ anti-human CD19 Antibody

Pricing & Availability
Clone
HIB19 (See other available formats)
Regulatory Status
RUO
Workshop
V CD19.11
Other Names
B4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HIB19_BV510_CD19_Antibody_FC_082512
Human peripheral blood lymphocytes were stained with CD3 APC and CD19 (clone HIB19) Brilliant Violet 510™.
  • HIB19_BV510_CD19_Antibody_FC_082512
    Human peripheral blood lymphocytes were stained with CD3 APC and CD19 (clone HIB19) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Quantity Check Availability Save
302241 25 tests 146€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302242 100 tests 313€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

 

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
  4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
  5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
  6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed
  2. Chen Y, et al. 2022. Sci Immunol. 7:eabp8328. PubMed
  3. McEvoy CM, et al. 2022. Nat Commun. 13:7634. PubMed
  4. Touizer E, et al. 2023. iScience. 26:105862. PubMed
  5. Musvosvi M, et al. 2023. Nat Med. 29:258. PubMed
  6. Collora JA, et al. 2022. Immunity. 55:1013. PubMed
  7. Parry H, et al. 2022. Cell Rep Med. 3:100739. PubMed
  8. Adamo S, et al. 2023. Cell Host Microbe. 31:928. PubMed
  9. Li C, et al. 2022. J Exp Med. 219:. PubMed
  10. Sannier G, et al. 2021. Cell Reports. 36(9):109643. PubMed
  11. Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed
  12. Krummey SM, et al. 2020. Cell Reports. 30(5):1282-1291.e5.. PubMed
  13. Lagou V et al. 2018. Cell reports. 25(3):798-810 . PubMed
  14. Schlicher L, et al. 2022. Int J Mol Sci. 23:. PubMed
  15. Groß R, et al. 2022. EBioMedicine. 75:103761. PubMed
  16. Kokkinopoulos I, et al. 2021. Sci Rep. 11:15759. PubMed
  17. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  18. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  19. Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed
  20. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  21. Catapano M, et al. 2020. J Invest Dermatol. 140:816. PubMed
  22. Pape KA, et al. 2021. Cell Rep. 37:109823. PubMed
  23. Kuri-Cervantes L, et al. 2020. STAR Protoc. 1:100154. PubMed
  24. Demers K, et al. 2016. PLoS Pathog. 12: 1005805. PubMed
  25. Hu EY, et al. 2021. Blood Adv. 5:3152. PubMed
  26. van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
  27. Yarmarkovich M, et al. 2021. Nature. 599:477. PubMed
  28. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  29. Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed
  30. Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed
  31. Bäcker-Koduah P, et al. 2020. Ann Clin Transl Neurol. 1.422222222. PubMed
  32. Rutishauser L, et al. 2017. AIDS Res Hum Retroviruses . 10.1089/AID.2016.0324. PubMed
  33. Pape KA, et al. 2022. JCI Insight. 7:. PubMed
  34. Hu EY, et al. 2020. JCI Insight. 5:00. PubMed
  35. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  36. Tong P, et al. 2021. Cell. :. PubMed
  37. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  38. Gao Y, et al. 2022. Immunity. 55:1732. PubMed
  39. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  40. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  41. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  42. Pucino V, et al. 2020. Cell Metabolism. 30(6):1055-1074.e8.. PubMed
  43. Shih T, et al. 2019. Front Immunol. 10:1652. PubMed
  44. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  45. Rakshit S, et al. 2020. Cell Rep. 33:108451. PubMed
  46. Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed
  47. Sekine T, et al. 2020. Cell. 183:158. PubMed
  48. NULL, et al. 2022. Cell. 185:916. PubMed
  49. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  50. Ruella M, et al. 2018. Nat Med. 24:1499. PubMed
  51. Chen Y, et al. 2020. Cell. 1496:183. PubMed
  52. Danzer H, et al. 2020. Elife. 9:00. PubMed
  53. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
  54. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  55. Sung JA, et al. 2018. Mol Ther. 26:2496. PubMed
  56. Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed
  57. Vanderbeke L, et al. 2021. Nat Commun. 12:4117. PubMed
  58. Giron LB, et al. 2020. EBioMedicine. 73.94791667. PubMed
  59. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  60. Upasani V, et al. 2019. Front Immunol. 2.152777778. PubMed
RRID
AB_2561668 (BioLegend Cat. No. 302241)
AB_2561668 (BioLegend Cat. No. 302242)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 95 kD
Distribution

B lineage (except plasma cells), follicular dendritic cells

Function
B cell activation and differentiation
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID
930 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD19 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD19 HIB19 FC
Biotin anti-human CD19 HIB19 FC
FITC anti-human CD19 HIB19 FC
PE anti-human CD19 HIB19 FC
PE/Cyanine5 anti-human CD19 HIB19 FC
Purified anti-human CD19 HIB19 FC,CyTOF®,IHC-F
APC/Cyanine7 anti-human CD19 HIB19 FC
PE/Cyanine7 anti-human CD19 HIB19 FC
Alexa Fluor® 488 anti-human CD19 HIB19 FC,ICC
Alexa Fluor® 647 anti-human CD19 HIB19 FC,IHC-F
Pacific Blue™ anti-human CD19 HIB19 FC
Alexa Fluor® 700 anti-human CD19 HIB19 FC
PerCP anti-human CD19 HIB19 FC
PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
Brilliant Violet 421™ anti-human CD19 HIB19 FC,ICC,IHC-F
Brilliant Violet 570™ anti-human CD19 HIB19 FC
Brilliant Violet 650™ anti-human CD19 HIB19 FC
Brilliant Violet 785™ anti-human CD19 HIB19 FC
Brilliant Violet 510™ anti-human CD19 HIB19 FC
Brilliant Violet 605™ anti-human CD19 HIB19 FC
Brilliant Violet 711™ anti-human CD19 HIB19 FC
Purified anti-human CD19 (Maxpar® Ready) HIB19 FC,CyTOF®
Alexa Fluor® 594 anti-human CD19 HIB19 ICC,IHC-F
PE/Dazzle™ 594 anti-human CD19 HIB19 FC
PE anti-human CD19 HIB19 FC
APC/Fire™ 750 anti-human CD19 HIB19 FC
Pacific Blue™ anti-human CD19 HIB19 FC
APC anti-human CD19 HIB19 FC
PE/Cyanine7 anti-human CD19 HIB19 FC
TotalSeq™-A0050 anti-human CD19 HIB19 PG
Brilliant Violet 750™ anti-human CD19 HIB19 FC
TotalSeq™-B0050 anti-human CD19 HIB19 PG
TotalSeq™-C0050 anti-human CD19 HIB19 PG
PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
Spark NIR™ 685 anti-human CD19 HIB19 FC
Ultra-LEAF™ Purified anti-human CD19 HIB19 FC,CyTOF®,Block,IHC
APC/Fire™ 810 anti-human CD19 HIB19 FC
PE/Fire™ 640 anti-human CD19 HIB19 FC
PE/Fire™ 700 anti-human CD19 HIB19 FC
TotalSeq™-D0050 anti-human CD19 HIB19 PG
Spark YG™ 593 anti-human CD19 HIB19 FC
GMP Pacific Blue™ anti-human CD19 HIB19 FC
Spark Violet™ 423 anti-human CD19 HIB19 FC
GMP PE anti-human CD19 HIB19 FC
GMP APC anti-human CD19 HIB19 FC
KIRAVIA Blue 520™ anti-human CD19 HIB19 FC
GMP PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
GMP PE/Cyanine7 anti-human CD19 HIB19 FC
Spark Violet™ 500 anti-human CD19 HIB19 FC
PE/Fire™ 810 anti-human CD19 HIB19 FC
Spark Violet™ 423 anti-human CD19 HIB19 FC
Spark UV™ 387 anti-human CD19 HIB19 FC
APC/Fire™ 750 anti-human CD19 HIB19 FC
PE/Cyanine5 anti-human CD19 HIB19 FC
Alexa Fluor® 660 anti-human CD19 HIB19 FC
PerCP/Fire™ 806 anti-human CD19 HIB19 FC
PerCP/Fire™ 780 anti-human CD19 HIB19 FC
Spark PLUS UV395™ anti-human CD19 HIB19 FC
Spark Red™ 718 anti-human CD19 HIB19 FC
FITC anti-human CD19 HIB19 FC
Go To Top Version: 2    Revision Date: 12/18/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account